Showing results (41-50 of 49) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
The Journal of Infection|November 17, 2011
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The NetherlandsDavid R Strutton, Raymond A Farkouh, Stephanie R Earnshaw, et al.Respiratory Medicine|November 18, 2008
Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPDStephanie R Earnshaw, Michele R Wilson, Anand A Dalal, et al.Clinicoeconomics and Outcomes Research : CEOR|July 2, 2016
Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of ChinaNingying Mao, Beth Lesher, Qifa Liu, et al.Current Medical Research and Opinion|November 25, 2014
Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costsMelea A Ward, Gang Fang, Kristy L Richards, et al.Journal of Health Economics and Outcomes Research|September 4, 2023
Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid LeukemiaMelea A Ward, Gang Fang, Kristy L Richards, et al.Environment International|June 1, 2014
Comparing measured and modelled PFOS concentrations in a UK freshwater catchment and estimating emission ratesMark R Earnshaw, Alexander G Paul, Robert Loos, et al.Infectious Diseases and Therapy|April 10, 2020
Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective AnalysisMichele R Wilson, Matthew D Wasserman, Marie-Claude Breton, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 9, 2008
Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuityJonathan C Javitt, Gergana P Zlateva, Stephanie R Earnshaw, et al.Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 9, 2002
Optimal allocation of resources across four interventions for type 2 diabetesStephanie R Earnshaw, Anke Richter, Stephen W Sorensen, et al.Pageof 5